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Abstract
Background: Improved cancer survival poses important questions about future life conditions of the survivor. We examined
the possible influence of a breast cancer diagnosis on subsequent working and marital status, sickness absence and income.
Materials: We conducted a matched cohort study including 4,761 women 40–59 years of age and registered with primary
breast cancer in a Swedish population-based clinical register during 1993–2003, and 2,3805 women without breast cancer.
Information on socioeconomic standing was obtained from a social database 1 year prior and 3 and 5 years following the
diagnosis. In Conditional Poisson Regression models, risk ratios (RRs) and 95% confidence intervals (CIs) were estimated to
assess the impact of a breast cancer diagnosis.
Findings: Three years after diagnosis, women who had had breast cancer more often had received sickness benefits
(RR=1.49, 95% CI 1.40–1.58) or disability pension (RR=1.47, 95% CI 1.37–1.58) than had women without breast cancer. We
found no effect on income (RR=0.99), welfare payments (RR=0.98), or marital status (RR=1.02). A higher use of sickness
benefits and disability pension was evident in all stages of the disease, although the difference in use of sickness benefits
decreased after 5 years, whereas the difference in disability pension increased. For woman with early stage breast cancer,
the sickness absence was higher following diagnosis among those with low education, who had undergone mastectomy,
and had received chemo- or hormonal therapy. Neither tumour size nor presence of lymph nodes metastasis was associated
with sickness absence after adjustment for treatment.
Interpretation: Even in early stage breast cancer, a diagnosis negatively influences working capacity both 3 and 5 years
after diagnosis, and it seems that the type of treatment received had the largest impact. A greater focus needs to be put on
rehabilitation of breast cancer patients, work-place adaptations and research on long-term sequelae of treatment.
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Introduction
Cancer survival has improved during the last decades, particu-
larly for patients diagnosed with breast cancer[1,2], the most
common cancer in women. New and better combinations of
treatments (chemotherapy, hormonal therapy, and radiothera-
py)[3,4,5] as well as earlier detection through mammography
screening programs[6,7,8] have contributed to the improved
prognosis. However, cancer and its treatment may cause both
physical and psychological problems that may influence ones future
life situation. Several recent studies have also addressed issues
related to employment and predictors of returning to work, such as
the effect of age, education, type of job, workplace adaptations,
adjuvant treatment and recurrences [9,10,11,12,13,14,15], or time
to return to work [16,17,18], among women diagnosed with breast
cancer. Other aspects of life in terms of marital status and risk of
divorce after a cancer diagnosis have also been studied
[19,20,21,22] where both negative and no effect have been found.
For deeper analysis we used the opportunity in Sweden to link
information from several population based registers enabling us not
only to investigate the effect of breast cancer on the future life
situationinthelongterm(both3and 5yearsafterthediagnosis),but
also to relate the findings to stage at diagnosis and the treatment
received.
In the present study we used information retrieved through
record linkage between three population-based registries to
investigate possible socioeconomic consequences of breast
cancer survivors in terms of sickness benefits, marital status,
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f o l l o w i n gab r e a s tc a n c e rd i a g n o s is. The investigation was made
possible by comparing breast cancer patients with women
w i t h o u tb r e a s tc a n c e rr a n d o m l ys e l e c t e df r o mt h es a m e
population. We also investigate dt h ep o s s i b l ei n f l u e n c eo f
tumour characteristics and type of cancer treatment on the
likelihood of returning to work.
Materials and Methods
This study was based on a dataset generated by record linkage
between three population-based registers, the Regional Quality
Register of Breast Cancer of the Uppsala/O ¨ rebro Region in
Central Sweden, the National Population Register, and the LISA-
database (an integrated database for labour market research).
Linkage was made possible by the individually unique National
registration number assigned to each resident in Sweden at birth
or time of permanent residency.
Regional Quality Register of Breast cancer
The Regional Quality Register of Breast Cancer in the
Uppsala/O ¨ rebro health care region covers seven counties in
central Sweden with a source population of 1.9 million
(representing about 20% of Sweden’s total population). The main
purpose of the register is to monitor the quality of care based on
regional or national guidelines for breast cancer management. The
register includes individual information reported continuously
from the clinicians on date of diagnosis, detection mode, tumour-
stage, tumour characteristics and primary surgical and oncological
treatment for all newly diagnosed breast cancer patients. The
database is continuously updated against the National Population
Register to assess current vital status of the registered patients. The
Regional Quality Register of Breast Cancer was started in 1992
and has been estimated to have a coverage of 97%, following a
validation against the records of the mandatory Swedish National
Cancer Register[23].
The National Population Register
This register, which is the basic register of the population of
Sweden, contains information about who lives in Sweden and
place of residence. The register is managed by the Swedish Tax
Agency[24].
The LISA-database (Social Database)
Individual information on socioeconomic and demographic
factors was obtained from the LISA-database managed by
Statistics Sweden[25]. This nationwide database, which integrates
existing data from registers in the labour market-, educational- and
social sector, consists of data from 1990 and onwards on all
individuals 16 years or older registered as living in Sweden. The
database is updated on a yearly basis regarding individual
information on educational level, income, socioeconomic index,
welfare benefits and employment status.
Study subjects and Follow-up
Study period. We investigated patients reported to the
Uppsala/O ¨ rebro Regional Quality Register of Breast Cancer
between January 1, 1993 and December 31, 2003.
Follow-up. Information from LISA was collected for the
years 1992 (1 calendar year prior to the patients with the earliest
diagnosis year) to 2006. This means that we had a follow-up of 5
years for all women diagnosed between 1993 and 2001, but a
follow-up limited to 3 years for women diagnosed between 2002
and 2003 (Table 1).
Women with breast cancer. This group was defined as all
women aged 20–59 years with a diagnosis of primary invasive
breast cancer between January 1, 1993 and December 31, 2003
and reported to the Uppsala/O ¨ rebro Regional Quality Register of
Breast Cancer. Since we were interested to investigate the
consequences of cancer on those who we were able to follow for
5 years or more (or 3 years for women diagnosed between 2002
and 2003), women with incomplete follow-up were excluded. In
the initial database of 5482 patients, 4413 were diagnosed between
Table 1. Patients 20–59 years of age with a breast cancer diagnosis between 1993 and 2003 matched with women without breast
cancer by birth year, gender and community.
1 calendar year prior to the diagnosis 3 calendar years after the diagnosis 5 calendar years after the diagnosis
Breast
cancer
Not breast
cancer
Breast
cancer
Not breast
cancer
Breast
cancer
Not breast
cancer %
No. No. % No. No. % No. No. %
Diagnosis year
1993 321 1605 6.7 321 1605 6.7 321 1605 8.5
1994 373 1865 7.8 373 1865 7.8 373 1865 9.9
1995 411 2055 8.6 411 2055 8.6 411 2055 10.9
1996 407 2035 8.6 407 2035 8.6 407 2035 10.8
1997 411 2055 8.6 411 2055 8.6 411 2055 10.9
1998 489 2445 10.3 489 2445 10.3 489 2445 13.0
1999 455 2275 9.6 455 2275 9.6 455 2275 12.1
2000 433 2165 9.1 433 2165 9.1 433 2165 11.5
2001 475 2375 10.0 475 2375 10.0 475 2375 12.6
2002 446 2230 9.4 446 2230 9.4 - - -
2003 540 2700 11.3 540 2700 11.3 - -
Total 4761 23805 4761 23805 3775 18875
doi:10.1371/journal.pone.0018040.t001
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4413 women diagnosed between 1993 and 2001, 3776 (85.6%)
could be followed for 5 years, and of the 1069 women diagnosed
between 2002 and 2003, 986 (92.2%) could be followed for 3
years. This means that from the initially identified 5482 patients,
721 were lost to follow-up and therefore excluded. The main
reason for failure to follow-up was death, i.e. 94.8% (676 of 721) of
the women had died within the follow-up period. The other main
reason for lost follow-up was that the women had moved out of the
health care region. Proportionally more women with advanced
stages (III-IV) were lost to follow-up than were women in earlier
stages, i.e. of the original sample 89% (4095/4587) of women with
stages I-IIB could be followed compared to 64% (225/354) of the
women with stages III-IV. Also, the women lost to follow-up were
proportionally younger, i.e. of women younger than 44 years of
age 83% could be followed (898/1080=83%) compared to 88%
(3863/4394) of women aged 45-59 years (data not shown). In one
prior study we also found that younger women had a poorer 5 year
relative survival after breast cancer[26].
Women without breast cancer. Each patient was
individually matched to 5 women without breast cancer (total
23805 women) registered in the National Population Register with
complete follow-up by birth year, and community one year prior
to the breast cancer patients’ calendar year of diagnosis. The main
reason for matching was to minimise confounding that may
influence the outcome of investigated variables, such as working
status and income. The matching was conducted by Statistics
Sweden, and made possible by use of the National registration
number (the individuals unique National registration number is
registered in all registers used in this study and all information
about an individual is attached to his/her unique number) and
information available in the National Population Register (where
also historical information on residential community is available).
Information collected from the Registers
Regional Quality Register of Breast Cancer. We retrieved
information on patients with early stage breast cancer classified
according to tumour stage [UICC stages I, IIa, IIb], tumour-size
in millimetre [1–10, 11–20, 21–50, 50+], lymph node involvement
[positive, negative], primary surgical treatment [mastectomy,
breast-conserving surgery (BCS), none or missing], and intended
oncological treatment [radiotherapy, chemotherapy, hormonal
therapy (Tamoxifen)]. We also investigated the effect of sentinel
node biopsy and axillary dissection [sentinel node only, axillary
dissection with 1–9 nodes examined, axillary dissection with more
than 10 nodes, missing]. Since the sentinel node procedure not
was fully introduced in our health care region until 2005, only few
node-negative patients were staged with this method in the study
cohort leading to low power and making it difficult to generalize
results.
The LISA-database. From this register we retrieved
individual information on all women 1 calendar year prior to
the breast cancer patients diagnosis as well as 3 and 5 years after
the year of diagnosis on education [low (compulsory school which
is mandatory, #9 years,), middle (gymnasium/upper secondary
school, 10–12 years), high (college and university, 13 or more
years), unknown], working at least part-time [yes, no],
unemployment [yes, no], retirement [yes, no], use of welfare
[social welfare allowance and/or housing allowance, yes, no],
marital status [married/registered partner, single (includes
cohabitants without registered partnership), divorced, widowed]
and number of people in the household [1, 2 or more].
Sickness absence. The social insurance system in Sweden
covers everyone that resides or works in Sweden, and provides
financial protection for persons with a disability or in connection
with an illness. Sick pay can be obtained (from the employer) the
first 14 days of a sick period. Sickness benefit is paid by the Swedish
Social Insurance Agency if the employee is ill for a longer period
than 14 days. The sickness benefit is approximately 80% of the
individuals income up to a certain limit (a year wage of SEK
321 000). Sickness pension (or disability compensation) can be
received if the work capacity is permanently reduced by at least a
quarter. Full income-related sickness compensation provides 64%
of the individuals assumed income. Sickness absence in our study
was defined as all women registered during the year of follow-up
with sickness benefit or disability pension at least part time [yes,
no]. We also presented the values of sickness benefit [yes, no], and
disability pension [yes, no].
Disposable income. The disposable income is the
individual’s total income (from all sources) minus taxation. To
show possible differences in income 1 year prior to diagnosis
between women with and without breast cancer we categorized
income as lowest 25%, 25–50%, 50–75% and 75–100% (Table 2).
To investigate changes in income after the disease, we compared
each individual’s income 3 and 5 years after the diagnosis with
that 1 year prior to the year of diagnosis, i.e. we investigated
whether they had had a 10% income increase or a 20% income
increase.
Outcome. Due to the social insurance system in Sweden (see
above) it is difficult to use either employment or income as an
outcome variable. A person could be registered as working full-
time if he/she is on sick-leave up to 100% from full-time work.
Also, the disposable income (up to a certain income level as
mentioned above) is not affected to a great extent. We therefore
chose to use sickness absence as our main outcome variable.
Statistical methods
In order to compare women diagnosed with breast cancer with
their matched controls 1 year prior to diagnosis, percentages in
various categories of the following variables were compared:
education, working at least part time, sickness absence, unem-
ployment, retirement, welfare, disposable income, marital status,
and number of people living in the household. To quantify the
differences between the two groups conditional logistic regression
was used to account for the matching with differences reported as
odds ratios (OR) with 95% confidence intervals (CI). Only
unadjusted estimates are reported, as the main interest was to
investigate whether there were any imbalances between the groups
before the women with breast cancer had been diagnosed
(Table 2).
In order to investigate differences in working life, income and
marital status in women diagnosed with breast cancer with their
matched controls at 3 and 5 years post diagnosis, conditional
Poisson regression was used to estimate a risk ratio (RR) with a
95% CI. A separate model was fitted for each factor of interest
with each model adjusted for education level and the factor of
interest recorded 1 year prior to diagnosis (Table 3).
In order to compare the effect of stage at diagnosis and
treatment on sickness absence at 3 and 5 years post diagnosis for
women diagnosed with breast cancer, unconditional logistic
regression was used with differences reported as odds ratios with
95% CIs. The following factors were investigated, working 1 year
before diagnosis, education, tumour size, having lymph nodes,
sentinel node, stage, and treatment. For each variable two models
were compared; the first model adjusted for education and the
factor of interest one year prior to diagnosis and the second model
adjusted for education and the factor of interest one year prior to
diagnosis and the remaining investigated factors (Table 4).
Breast Cancer Survivors
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Differences 1 year prior to diagnosis (Table 2)
Compared to women with low education, the risk of breast
cancer was higher for women with high (OR=1.21, 95% CI 1.11–
1.32) and middle (OR=1.13, 95% CI 1.05–1.23) education. Also,
the risk of a breast cancer diagnosis was somewhat higher among
women who worked (OR=1.14, 95% CI 1.04–1.26), and lower
among women who had received welfare allowance (OR=0.87,
95% CI 0.78–0.97) (Table 2). No significant associations were
Table 2. Education, working life, income and marital status 1 year before diagnosis among women diagnosed with breast cancer
between 1993 and 2003 and women without breast cancer.
1 year prior to diagnosis
Women with breast
cancer
Women without breast
cancer Crude model
No. % No. % OR 95% CI
Education
Low 1155 24.3 6434 27.0 1.00 (ref.)
Middle 2191 46.0 10828 45.5 1.13 1.05–1.23
High 1398 29.4 6451 27.1 1.21 1.11–1.32
Unknown 17 0.4 92 0.4 1.04 0.62–1.75
Working (part-time or more)
1
Yes 4196 88.1 20637 86.7 1.14 1.04–1.26
No 565 11.9 3168 13.3 1.00 (ref.)
Sickness benefit
Yes 944 19.8 4579 19.3 1.04 0.96–1.12
No 3817 80.2 19226 80.8 1.00 (ref.)
Disability pension
Yes 572 12.0 3062 12.9 0.92 0.84–1.02
No 4189 88.0 20743 87.1 1.00 (ref.)
Sickness absence
2
Yes 3395 71.3 16830 70.7 0.97 0.91–1.04
No 1365 28.7 6975 29.3 1.00 (ref.)
Unemployment
3
Yes 694 14.6 3321 14.0 1.05 0.94–1.15
No 4067 85.4 20484 86.1 1.00 (ref.)
Welfare
4
Yes 464 9.8 2609 11.0 0.87 0.78–0.97
No 4297 90.3 21196 89.0 1.00 (ref.)
Disposable income
01–25% 1176 24.7 5982 25.1 1.00 (ref.)
26–50% 1127 23.7 6022 25.3 0.95 0.87–1.04
51–75% 1232 25.9 5898 24.8 1.06 0.97–1.06
76–100% 1226 25.8 5903 24.8 1.06 0.97–1.16
Marital status
Married/Partner 3000 63.0 14968 62.9 1.00 (ref.)
Single
5 788 16.6 4016 16.9 0.98 0.89–1.07
Divorced 827 17.4 4152 17.4 0.99 0.91–1.08
Widowed 146 3.1 669 2.8 1.09 0.91–1.31
No of people in the household
1 1050 22.1 5068 21.3 1.00 (ref.)
2 or more 3711 78.0 18737 78.7 0.96 0.89–1.03
Total no. 4761 23805
1Working or studying at least part time. Self-employed included.
2Includes all women with disability pension at least part-time and/or with sickness benefit.
3Including women who part time registered as unemployed or more.
4Social welfare allowance (own) and/or housing allowance (own).
5Includes cohabitants without registered partnership.
doi:10.1371/journal.pone.0018040.t002
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income, marital status or household size (Table 2).
Differences 3 and 5 years after the diagnosis (Table 3)
Breast cancer had a post diagnostic effect both 3 and 5 years
after the diagnosis on sickness benefits and disability pension
(Table 3). In the third year after diagnosis, a larger proportion of
women with breast cancer had received sickness benefit
compared to women without breast cancer (risk differ-
ence=9.7%, RR=1.49, 95% CI 1.40–1.58), or had received
disability pension (risk difference=5.2%, RR=1.47, 95% CI
1.37–1.58 (Table 3). The same pattern was present after 5 years,
with a larger proportion of women with breast cancer, compared
to women without breast cancer, receiving sickness benefit (risk
difference=4.6%, RR=1.24, 95% CI 1.15–1.33), or disability
pension (risk difference=7.5%, RR=1.47, 95% CI 1.37–1.58),
although the difference in sickness benefit had decreased and the
difference in disability pension had increased (Table 3). We
found no influence of breast cancer on income, welfare use or
marital status either 3 or 5 years after diagnosis, whereas breast
cancer had a borderline effect on working part-time or less
(Table 3).
Sickness benefit and disability pension in relation to
stage at diagnosis (Figure 1)
Figure 1 displays the effect of a breast cancer diagnosis stratified
by tumour stage on sickness benefit and disability pension 3 and 5
years after diagnosis. There was a statistically significant effect of
breast cancer on sickness benefit and disability pension in all
stages, but the effect seemed to be stronger in more advanced
stages. Also the effect of sickness benefit was much greater at 3
years compared to 5 years after diagnosis, whereas the effect on
disability pension had increased after 5 years.
The proportion of women who had received sickness benefit
was after 3 years 19.2% among women without breast cancer,
compared to 25.3%, 33.0%, and 38.2% in women with breast
cancer stage I, II, III-IV, respectively and after 5 years 19.7%
among women without breast cancer, compared to 23.9%, 26.2%,
and 22.1% in women with breast cancer stage I, II, III-IV,
respectively.
The proportion of women with disability pension was after 3
years 19.3% among women without breast cancer, compared to
22.6%, 26.1%, and 28.0% in women with breast cancer stage I,
II, III-IV respectively, and after 5 years 21.7% among women
without breast cancer, compared to 26.1%, 32.5%, and 34.3% in
Table 3. Working life, income and marital status 3 and 5 years following a breast cancer diagnosis between 1993 and 2003 and
matched women without breast cancer.
3 years after diagnosis 5 years after diagnosis
Adjusted model
6 Adjusted model
6
No./Total % RR 95% CI No./Total % RR 95% CI
Working (part-time or more)
1 Not breast cancer 19555/23805 82.2 1.00 (ref.) 14761/18875 78.2 1.00 (ref.)
Breast cancer 3860/4761 81.1 0.97 0.94–1.01 2881/3775 76.3 0.96 0.93–1.00
Sickness benefit Not breast cancer 4698/23805 19.7 1.00 (ref.) 3708/18875 19.7 1.00 (ref.)
Breast cancer 1398/4761 29.4 1.49 1.40–1.58 917/3775 24.3 1.24 1.15–1.33
Disability pension Not breast cancer 4597/23805 19.3 1.00 (ref.) 4100/18875 21.7 1.00 (ref.)
Breast cancer 1168/4761 24.5 1.47 1.37–1.58 1103/3775 29.2 1.47 1.37–1.58
Sickness absence
2 Not breast cancer 8384/23805 35.2 1.00 (ref.) 7035/18875 37.3 1.00 (ref.)
Breast cancer 2204/4761 46.3 1.36 1.30–1.43 1788/3775 47.4 1.31 1.24–1.38
Unemployed
3 Not breast cancer 2893/23805 12.2 1.00 (ref.) 2093/18875 11.1 1.00 (ref.)
Breast cancer 555/4761 11.7 0.95 0.86–1.05 376/3775 10.0 0.90 0.80–1.01
Welfare
4 Not breast cancer 1584/23805 6.7 1.00 (ref.) 1004/18875 5.3 1.00 (ref.)
Breast cancer 275/4761 5.8 0.98 0.85–1.13 165/3775 4.4 0.88 0.73–1.06
Income increase with Not breast cancer 12517/23805 52.6 1.00 (ref.) 11941/18875 63.3 1.00 (ref.)
10% or more Breast cancer 2414/4761 50.7 0.99 0.96–1.01 2344/3775 62.1 0.99 0.96–1.01
Income increase with Not breast cancer 7714/23805 32.4 1.00 (ref.) 8944/18875 47.4 1.00 (ref.)
20% or more Breast cancer 1459/4761 30.6 0.99 0.97–1.02 1701/3775 45.1 0.98 0.95–1.01
Are married
5 Not breast cancer 14476/23805 60.8 1.00 (ref.) 11494/18875 60.9 1.00 (ref.)
Breast cancer 2955/4761 62.1 1.02 0.98–1.07 2356/3775 62.4 1.02 0.97–1.07
Divorced Not breast cancer 4630/23805 19.5 1.00 (ref.) 3721/18875 19.7 1.00 (ref.)
Breast cancer 889/4761 18.7 0.95 0.87–1.05 720/3775 19.1 1.00 0.90–1.10
Single household Not breast cancer 6111/23805 25.7 1.00 (ref.) 5144/18875 27.3 1.00 (ref.)
Breast cancer 1209/4761 25.4 0.95 0.88–1.02 1013/3775 26.8 0.94 0.88–1.02
1.Working or studying at least part time. Self-employed included.
2.Includes all women with disability pension at least part-time and/or with sickness benefit.
3.Including women who are part time registered as unemployed or more.
4.Social welfare allowance (own) and/or housing allowance (own).
doi:10.1371/journal.pone.0018040.t003
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(Figure 1).
Sickness absence among women with early stage breast
cancer (stage I-IIb) in relation to tumour characteristics
and treatment (Table 4)
3 years after diagnosis. After adjustment for sickness
absence and education 1 year prior to the diagnosis, the
likelihood for women with stage I-IIb disease to be on sick leave
was positively associated with larger tumours, lymph node
metastasis, treatment by mastectomy and receiving adjuvant
chemo- or hormonal therapy, whereas treatment by
radiotherapy had no effect (Model 1, Table 4). After adjustment
for treatment neither tumour size nor lymph nodes had any effect
(Model 2, Table 4).
5 years after diagnosis. The effects of tumour
characteristics and treatment were somewhat weaker compared
to those after 3 years except that of education. The likelihood of
women with stage I-IIb disease to be on sickness absence was
Table 4. Odds ratios (OR) and 95% confidence intervals (CI) of sickness absence 3 and 5 years following a diagnosis of stage I-IIb
breast cancer.
Sickness absence after 3 years Sickness absence after 5 years
Yes Model 1 Model 2 Yes Model 3 Model 4
No./Total % OR 95% CI OR 95% CI No./Total % OR 95% CI OR 95% CI
Sickness absence 1 year prior
Yes 933/1169 79.8 1.00 (ref.) 1.00 (ref.) 685/868 78.9 1.00 (ref.) 1.00 (ref.)
No 946/2925 32.3 0.12 0.10–0.15 0.12 0.10–0.14 863/2375 36.3 0.16 0.13–0.19 0.15 0.13–0.19
Education 1 year before
Low 528/1006 52.5 1.00 (ref.) 1.00 (ref.) 461/841 54.8 1.00 (ref.) 1.00 (ref.)
Middle 857/1881 45.6 0.88 0.75–1.05 0.89 0.75–1.06 691/1451 47.6 0.85 0.71–1.03 0.86 0.71–1.03
High 490/1197 40.9 0.84 0.70–1.02 0.83 0.68–1.00 394/943 41.8 0.77 0.63–0.94 0.76 0.61–0.93
Unknown 4/11 36.4 0.57 0.14–2.25 0.49 0.12–2.00 2/8 25.0 0.50 0.10–2.49 0.44 0.09–2.23
Tumour size
1–10 336/819 41.0 1.00 (ref.) 1.00 (ref.) 284/639 44.4 1.00 (ref.) 1.00 (ref.)
11–20 907/2047 44.3 1.15 0.96–1.38 1.01 0.84–1.22 755/1632 46.3 1.09 0.90–1.34 1.02 0.83–1.26
21–50 610/1183 51.6 1.66 1.36–2.03 1.14 0.91–1.42 490/933 52.2 1.49 1.20–1.86 1.18 0.93–1.51
50+ 26/46 56.5 2.19 1.15–4.18 1.47 0.76–2.88 19/39 48.7 1.25 0.62–2.50 0.98 0.48–2.02
Lymph nodes
N0 1189/2732 43.5 1.00 (ref.) 1.00 (ref.) 992/2165 45.8 1.00 (ref.) 1.00 (ref.)
N+ (Yes) 690/1363 50.6 1.49 1.29–1.72 1.00 0.83–1.21 556/1078 51.6 1.36 1.16–1.59 1.08 0.88–1.33
Sentinel node
Sentinel node only 116/278 41.2 1.00 (ref.) 25/56 44.6 1.00 (ref.)
Axillary dissection (1–9) 661/1525 43.3 1.26 0.94–1.69 630/1313 48.0 1.41 0.78–2.54
Axillary dissection (10+) 1096/2279 48.1 1.59 1.20–2.12 889/1863 47.7 1.44 0.80–2.59
Missing 6/13 46.2 1.18 0.33–4.24 4/11 36.4 0.68 0.15–3.04
Surgery
Mastectomy 629/1193 52.7 1.00 (ref.) 1.00 (ref.) 503/955 52.7 1.00 (ref.) 1.00 (ref.)
Breast-conserving 1241/2881 43.7 0.62 0.53–0.72 0.71 0.59–0.86 1038/2272 45.7 0.72 0.61–0.85 0.77 0.63–0.95
None or missing 9/21 42.9 - - - - 7/16 43.8 - - - -
Received radiotherapy
Yes 1605/3539 45.4 0.90 0.74–1.10 0.99 0.78–1.26 1332/2796 47.6 1.03 0.83–1.28 1.12 0.86–1.44
No 274/556 49.3 1.00 (ref.) 1.00 (ref.) 216/447 48.3 1.00 (ref.) 1.00 (ref.)
Received chemotherapy
Yes 777/1483 52.4 1.74 1.51–2.01 1.55 1.29–1.86 558/1083 51.5 1.42 1.22–1.67 1.23 1.00–1.50
No 1102/2612 42.2 1.00 (ref.) 1.00 (ref.) 990/2160 45.8 1.00 (ref.) 1.00 (ref.)
Received hormonal therapy (Tamoxifen)
Yes 822/1629 50.5 1.35 1.17–1.55 1.25 1.08–1.46 537/1055 50.9 1.20 1.02–1.40 1.08 0.90–1.29
No 1057/2466 42.9 1.00 (ref.) 1.00 (ref.) 1911/2188 46.2 1.00 (ref.) 1.00 (ref.)
Model 1: Adjustment for sickness absence 1 year before diagnosis, education.
Model 2: Adjustment for sickness absence 1 year before diagnosis, education, tumour size, having lymph nodes, stage, and treatment.
Model 3: Adjustment for sickness absence 1 year before diagnosis, education.
Model 4: Adjustment for sickness absence 1 year before diagnosis, education, tumour size, having lymph nodes, stage, and treatment.
doi:10.1371/journal.pone.0018040.t004
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lymph node metastasis and treatment by mastectomy,
chemotherapy or hormonal therapy, whereas treatment by
radiotherapy had no effect (Model 3, Table 4). After adjustment
for treatment neither tumour size, the presence of lymph nodes
metastasis or hormonal therapy had any significant effect (Model
4, Table 4).
Chemotherapy and Hormonal treatment in relation to
type of sickness absence. After adjustment for tumour
characteristics, treatment by chemotherapy increased the risk for
sickness benefit in the 3’rd but not in the 5’th year after diagnosis
(RR=1.67, 95% CI 1.40–2.00, and RR=1.10, 95% CI 0.89–
1.36 respectively), but had no effect on the risk for disability
pension either 3 or 5 years after diagnosis (RR=1.10, 95% CI
0.86–1.41, and RR=1.24, 95% CI 0.98–1.57 respectively).
Hormonal treatment also increased the risk for sickness benefit 3
but not 5 years after diagnosis (RR=1.21, 95% CI 1.04–1.41, and
RR=0.93, 95% CI 0.76–1.12 respectively), but did, in contrast to
chemotherapy, have an effect on the risk for disability pension
both 3 or 5 years after diagnosis (RR=1.47, 95% CI 1.19–1.80,
and RR=1.40, 95% CI 1.13–1.72 respectively) (data not shown).
Sentinel node: The risk of sickness absence was higher among
patients with stage I-IIb breast cancer who had had axillary lymph
node dissection compared to sentinel node biopsy (Table 4).
Discussion
Although many cancer survivors are able to return to a normal
life and functioning following treatment, many women of working
ages do not. We found that a breast cancer diagnosis was
associated with an increased risk of at least part time sickness
benefit or disability pension even after 5 years, although the effect
on sickness benefit was weaker after 5 years. This pattern was
evident for all stages of disease at time of diagnosis, although it was
somewhat less pronounced in early stage disease. The negative
influence on working life was greater among women who had
undergone surgery by mastectomy or received chemotherapy or
hormonal treatment, treatment modalities which have known side-
effects. All observed associations were weaker after 5 years
compared to 3 years.
Strengths of the present study included the design with cases
identified in a large population based clinical register and the use
of matched controls in order to minimize confounding of the
socioeconomic variables, and also the baseline determination of
outcome variables at the age of one year before breast cancer
diagnosis for the cases. Weaknesses included absence of informa-
tion on recurrences and that the information in the clinical register
is limited to intended chemo- and hormonal treatment, with no
data available on actual treatment received. Especially since it is
known that adherence to hormonal therapy often is lower than
expected (65–85%) [27].
Contrary to findings in earlier studies[9], we did not find any
effect on working after 3 or 5 years between survivors of breast
cancer and controls. However, this could be explained by that the
working variable used cannot reveal whether an individual returns
to work to the same degree as she had before diagnosis, but only
that she works at least part of the time. When we used sickness
benefit and disability pension as endpoints, we found large
differences between cancer survivors and women without breast
cancer. Another Nordic study also indicated an increased risk of
early retirement among breast cancer survivors[12]. One obvious
reason for the detected differences on our study could be the
effects of advanced disease on future life situation, but we also
found differences among women diagnosed with early stage breast,
a group with a higher disease-free survival.
In contrast to other investigations[13,14,28] we did not find that
unemployment, use of welfare, or lower income was more
common among breast cancer survivors. However, a possible
explanation, at least in part, could be the Swedish social insurance
system, which guarantees a right to receive some sort of sick
compensation and that illness in itself does not constitute grounds
for dismissal according to Swedish legislation. Also, the disposable
income includes incomes from different sources (both earned by
employment, unemployment benefit, sickness benefit and insur-
Figure 1. Proportion of women, with and without breast cancer, who received sickness benefit or disability pension 3 and 5 years
following a diagnosis.
doi:10.1371/journal.pone.0018040.g001
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investigate any effects on labour earnings only. As reported by
others[19,20], change of marital status or divorce was not more
common among breast cancer survivors.
The major determinants for sickness absence after 5 years were
level of education and type of treatment. Low education, low
socioeconomic standing and having a manual job have previously
been reported to be risk factors for early retirement and
unemployment after a cancer diagnosis[12,13], although the risk
of unemployment was estimated as small. Perhaps differences in
the nature of working tasks, with more manual labour in lower
socioeconomic groups, is one important explanation for the
difference found between educational groups. Workplace accom-
modations have also been found to play an important role for
returning to work after cancer treatment[10].
Treatment by mastectomy and axillary dissection were also risk
factors for sickness absence after 3 and 5 years. Mastectomy has
also been reported as being associated with an increased risk for
chronic pain[29] or lymphoedema[30], compared to after breast
conserving surgery. Studies have also found that physical and
social function, general health[31], or role functioning[32] after a
mastectomy remains lower 5 years after the surgery compared to
after breast conserving surgery. Axillary lymph node dissection has
known side-effects such as lymphoedema, restricted shoulder
mobility, pain, and sensory disturbances. The risks of these side-
effects have been shown to be smaller when using sentinel node
biopsy[33,34,35,36]. In contrast to others[37], we did not find any
negative effect of receiving radiotherapy on sickness absence from
work despite the well-known side-effects associated with radio-
therapy towards the axilla and supraclavicular fossa[36].
Adjuvant chemotherapy, did however, negatively affect both
sickness benefit and disability pension after 3 years, but not after 5
years. This finding corroborates results from other studies
reporting short time effects of chemotherapy[15,17], or that
chemotherapy did not have any long time effect on quality of
life[3]. A recent Danish study did not find any associations
between chemotherapy and long term sequelae[37]. This implies
that most of the side-effects of chemotherapy that could affect
work (such as fatigue, nausea, and anxiety of this treatment) are
transient.
Adjuvant hormonal therapy did have a persistent impact on
disability pension even after 5 years, which is in line with prior
investigations associated with returning to work [11], whereas the
effect on sickness benefit decreased after 5 years. The Danish study
found a correlation between endocrine therapy and symptoms
affecting daily activities including stopping or changing work[37].
In Sweden, endocrine therapies are usually given for 5 years
following the end of primary treatment. In other words, most
women that were prescribed Tamoxifen in our study were still on
this treatment during follow-up, making it difficult to examine
possible post-treatment side-effects on working activity. However,
extended periods for endocrine treatments underline the impor-
tance of investigating side-effects. Especially considering that the
longer a person is away from work due to an illness, the harder it is
to return to the labour market[38,39]. Furthermore, even longer
treatment than 5 years has been recommended[40] which mean
that this question is of growing importance. The management of
side-effects is not only important with regard to quality of life and
working activity, but also in that it may influence adherence to
treatment in a way that ultimately can compromise the chance of
being cured of breast cancer.
Interpretation
Even in early stage breast cancer, the diagnosis was negatively
associated with sickness absence both 3 and 5 years after diagnosis,
and was most pronounced in women who underwent mastectomy
or received chemotherapy or hormonal treatment. The knowledge
about how to increase the number of women returning to full-time
work is rather unexplored, and a study has also found that many
cancer patients report unmet rehabilitation needs[41]. A greater
focus needs to be put on rehabilitation of breast cancer patients
(such as oedema, pain, psychological distress), investigation of
eventual positive effects of health-related lifestyle changes (such as
physical activity and diet), physical work-place adaptations and
research on long-term sequelae of treatment to receive a better
understanding of the women’s life-situation and to be able to target
efforts.
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